Varian Executive and Leadership Team

Jiahong Li, the Director, Finance & Chief Financial Officer (APAC) at Varian, directs financial operations and strategy across the Asia-Pacific region. This leadership role involves managing budgets, forecasting financial performance, and ensuring fiscal responsibility for Varian's operations in this critical market. Overseeing all financial planning and analysis, Jiahong Li drives profitability and sustainable growth by optimizing resource allocation and identifying key investment opportunities. The Chief Financial Officer (APAC) ensures compliance with regional financial regulations and implements robust internal controls to safeguard company assets. By providing strategic financial insights, Jiahong Li supports executive decision-making and contributes directly to Varian's global financial objectives. This executive's focus on financial integrity and strategic investment underpins the company's expansion and operational efficiency in the APAC territory.

Andrew Shogan, the President, Multi-Disciplinary Oncology at Varian, leads the strategic direction and operational execution for Varian's comprehensive oncology solutions. This executive role encompasses overseeing the integration and advancement of technologies across various cancer treatment modalities, including radiotherapy, radiosurgery, and brachytherapy. Shogan drives market growth and innovation by ensuring that Varian's product portfolio effectively addresses the complex needs of modern cancer care. The President, Multi-Disciplinary Oncology collaborates with global teams to enhance patient access to cutting-edge treatments and improve clinical workflows. By focusing on synergistic development across different oncology disciplines, Andrew Shogan strengthens Varian's position as a leader in delivering holistic cancer treatment solutions. This leadership ensures seamless patient journeys and superior therapeutic results.

Stephen Jamison, the President, Proton Solutions at Varian, spearheads the strategic growth and technological advancement of Varian's proton therapy offerings. This executive leadership position is critical for expanding access to this highly precise form of cancer treatment globally. Jamison directs the development, sales, and implementation of Varian's state-of-the-art proton therapy systems, ensuring they meet the highest standards of clinical efficacy and operational efficiency. Overseeing market penetration and strategic partnerships, Stephen Jamison drives Varian's leadership in the proton therapy sector. The President, Proton Solutions works to integrate proton therapy seamlessly into broader cancer treatment plans, enhancing patient outcomes and physician capabilities. This focus ensures Varian continues to innovate and lead in delivering advanced, targeted cancer therapies worldwide.

Sasa Mutic, the President, Radiation Oncology Solutions at Varian, directs the strategic vision and operational performance for Varian's extensive radiation oncology portfolio. This leadership role is central to advancing the company's mission of treating cancer with radiotherapy and radiosurgery. Mutic oversees product innovation, market development, and customer engagement across global markets, ensuring Varian's solutions empower clinicians to deliver superior patient care. The President, Radiation Oncology Solutions drives the integration of advanced technologies and software to optimize treatment planning and delivery. By fostering collaboration across R&D, sales, and service teams, Sasa Mutic enhances Varian's ability to provide comprehensive and effective radiation oncology treatments. This executive's leadership ensures Varian remains a trusted partner in the fight against cancer.

David Hahn, the Varian Interventional Solutions Vice President & Chief Medical Officer at Varian, guides the medical strategy and clinical direction for Varian's interventional solutions portfolio. This executive role involves ensuring that product development and market strategies align with the highest standards of patient care and clinical efficacy. Overseeing clinical research and medical affairs, David Hahn champions innovation in treatment modalities. The Chief Medical Officer (Interventional Solutions) collaborates closely with R&D and commercial teams to translate medical insights into market-leading products. By providing expert medical guidance, Hahn ensures Varian's interventional offerings meet the evolving needs of healthcare providers and patients worldwide. This leadership position is crucial for maintaining Varian's commitment to improving outcomes in cancer treatment and other medical conditions through advanced interventional technologies.

Dee Khuntia, the Senior Vice President, Medical Affairs & Chief Medical Officer at Varian, directs the company's comprehensive medical strategy and clinical excellence initiatives. This pivotal role ensures Varian's treatments and technologies, including radiotherapy and proton therapy, meet rigorous medical standards and deliver optimal patient outcomes. Overseeing global medical affairs, Khuntia fosters strong relationships with healthcare professionals and key opinion leaders, driving the adoption of Varian's advanced cancer treatment solutions. The Chief Medical Officer champions evidence-based medicine and guides clinical research to support product innovation and market expansion. By translating complex medical needs into actionable strategies, Dee Khuntia significantly influences the development and deployment of Varian's life-saving technologies across diverse international markets. This leadership ensures Varian remains at the forefront of oncological care.